

Machine Learning to Identify Patients at Risk of Inappropriate Dosing for Renal Risk Medications: A Critical Comment on Kaas-Hansen et al [Letter]

Morten Baltzer Houliind ¹⁻⁴, Esben Iversen ¹, Baker Nawfal Jawad ¹, Thomas Kallelose ¹, Mads Hornum ^{5,6}

¹Department of Clinical Research, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark; ²The Capital Region Pharmacy, Herlev, Denmark; ³Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark; ⁴Emergency Department, Copenhagen University Hospital – Amager & Hvidovre, Hvidovre, Denmark; ⁵Department of Nephrology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark; ⁶Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Correspondence: Morten Baltzer Houliind, Tel +45 28838563, Email morten.baltzer.houliind@regionh.dk

Dear editor

Kaas-Hansen et al use machine learning to identify hospitalized patients at high risk of receiving a medication with inappropriate dose according to renal function.¹ Medication dosing during hospitalization is challenging, and we acknowledge the efforts by Kaas-Hansen to develop a prediction tool for prescribing errors. We have previously reported that at least 10% of older patients in our emergency department receive at least one medication at a dose higher than what would be recommended based on their renal function.² Ultimately, we believe machine learning could address this challenge by helping clinicians identify patients most likely to receive inappropriate medication doses. However, Kaas-Hansen et al do not assess the clinical applicability, implementation, or future improvement of their models, so it is difficult to comment on the impact of their study. We also have some methodological concerns with their study design.

One potential issue is the use of pro.medicin.dk for dosing recommendations. Pro.medicin.dk is used by many Danish clinicians but has several limitations. First, pro.medicin.dk does not provide any references, so it is impossible to validate its accuracy. Second, the recommendations in pro.medicin.dk are often ambiguous. For example, the recommendation for most opioids is “in patients with renal impairment dose reduction should be considered”. In these cases, it is impossible to quantify the recommendation, which might explain why Kaas-Hansen studied only eight medications, none of which were opioids. Third, recommendations in pro.medicin.dk are based on GFR in body surface area (BSA)-normalized units (mL/min/1.73m²), but dose recommendations from drug manufacturers are typically given in absolute units (mL/min).³ Therefore, we believe it would have been more appropriate to calculate eGFR in absolute units and compare this to dose recommendations in the Summary of Product Characteristics for each medication.

The authors also do not consider the presence of acute kidney injury (AKI), which can affect the accuracy of GFR estimates and presents other challenges to medication dosing. In our own study of 339 older patients in the emergency department, we found that 33 patients (9.7%) met criteria for AKI within 48 hours of admission.⁴ We would be interested to see a sensitivity analysis by Kaas-Hansen et al where patients with suspected AKI are excluded. A more general issue with this kind of study is that GFR can fluctuate during hospitalization. Even in the absence of AKI, patients with chronic kidney disease (CKD) can have up to 7% fluctuation in GFR due to biological variation alone.⁵ Ideally, dosing of renal risk medications should be determined from the patient’s baseline GFR, which is difficult to assess during hospitalization. Kaas-Hansen et al define their primary outcome as eGFR below 30 mL/min/1.73m² at any point during hospitalization, but temporary reclassification of CKD category is not necessarily clinically relevant. Dosing medications according to the lowest GFR value during hospitalization could also lead to underdosing, which is itself problematic. For these reasons, it may be more useful to evaluate outcomes such as adverse drug events or rehospitalization.

Acknowledgments

This work was performed as part of the Clinical Academic Group (ACUTE-CAG) for Recovery Capacity funded by the Greater Copenhagen Health Science Partners (GCHSP).

Funding

Morten Baltzer Houliind was supported by a postdoctoral fellowship from The Capital Region's Research Foundation for Health Research, Denmark (grant-A6882).

Disclosure

The authors declare no conflicts of interest in relation to this communication.

References

1. Kaas-Hansen BS, Leal Rodríguez C, Placido D, et al. Using machine learning to identify patients at high risk of inappropriate drug dosing in periods with renal dysfunction. *Clin Epidemiol.* 2022;14:213–223. doi:10.2147/CLEP.S344435
2. Iversen E, Bodilsen AC, Klausen HH, et al. Kidney function estimates using cystatin C versus creatinine: impact on medication prescribing in acutely hospitalized elderly patients. *Basic Clin Pharmacol Toxicol.* 2019;124(4):466–478. doi:10.1111/bcpt.13156
3. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200841.pdf. Accessed May 20, 2022.
4. Walls AB, Bengaard AK, Iversen E, et al. Utility of suPAR and NGAL for AKI risk stratification and early optimization of renal risk medications among older patients in the emergency department. *Pharm Basel Switz.* 2021;14(9):843. doi:10.3390/ph14090843
5. Rowe C, Sitch AJ, Barratt J, et al. Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease. *Kidney Int.* 2019;96(2):429–435. doi:10.1016/j.kint.2019.02.021

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Epidemiology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Epidemiology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Epidemiology

Dovepress

Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access, online journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification, systematic reviews, risk & safety of medical interventions, epidemiology & biostatistical methods, and evaluation of guidelines, translational medicine, health policies & economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: <https://www.dovepress.com/clinical-epidemiology-journal>

<https://doi.org/10.2147/CLEP.S369602>